通过癌细胞系的瘤解来预测药物反应
Yu-Ching Hsu1,2,3,4, Yu-Chiao Chiu5,6, Tzu-Pin Lu3
1Bioinformatics Program, Taiwan International Graduate Program, National Taiwan University, Taipei 115, Taiwan.
Patterns (New York, N.Y.)
|April 22, 2024
概括
这项研究引入了Scaden-CA,这是一种深度学习模型,可以解构瘤数据以预测患者的药物反应. 这种方法弥合了用于癌症药物发现的体外和体内药基因组学数据之间的差距.
科学领域:
- 计算生物学是一种计算生物学.
- 基因组学就是基因组学.
- 药物基因组学 药物基因组学
背景情况:
- 患者药物反应数据有限,阻碍了药物基因组学研究.
- 在体外 (细胞系) 和体内 (患者) 数据之间的差距是具有挑战性的.
研究的目的:
- 开发一种深度学习模型 (Scaden-CA) 用于将瘤数据解成癌细胞系比例.
- 使用解密数据和细胞系敏感性信息创建药物反应预测方法.
主要方法:
- 训练了一个深度学习模型,Scaden-CA,用于瘤解卷.
- 使用癌症细胞系百科全书 (CCLE) 批量RNA数据验证了模型.
- 将模型应用于癌症基因组图谱 (TCGA) 数据集,用于药物反应预测.
主要成果:
- 在验证中,Scaden-CA表现出高性能,一致性相关系数>0.9和解卷率>70%.
- 该模型成功地将TCGA瘤数据分解成癌细胞系比例.
- 研究了预测的细胞活力和基因组特征之间的关联.
结论:
- Scaden-CA有效地解密瘤数据,使得药物反应的预测更为可靠.
- 这些发现支持药物重定向的潜力,通过识别与预测细胞活力相关的机制.
- 这项工作通过整合体外和体内数据来推进药物基因组学.
更多相关视频
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
4.9K
12:41Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
4.8K
相关概念视频
Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
